Open Thu 8:30am : 01582 842096
VioVet Insurance

Vetergesic Injection for Dogs & Cats

  • Multi-Dose » 10ml Bottle £38.26
  • Single Dose » 1ml Vial (Pack of 5) £15.35

Selection of 2 products from

£15.35 to £38.26

Description

Vetergesic is normally used to aid the control of pain in dogs and cats.

A prescription is required which we will confirm with the prescribing veterinary surgeon.

Vetergesic Multidose 0.3 mg/ml Solution for Injection for Dogs, Cats and Horses

Qualitative and quantitative composition

Qualitative composition

Buprenorphine 0.3 mg/ml, as Buprenorphine hydrochloride 0.324 mg /ml

Chlorocresol 1.35 mg/ml

Pharmaceutical form

Clear, colourless solution for injection

Clinical particulars

Target species

Dogs, Cats and Horses

Indications for use

Post-operative analgesia in the dog, cat and horse.

Potentiation of the sedative effects of centrally-acting agents in the dog and horse.

When used in horses, an intravenous sedative should be administered within five minutes prior to injection of buprenorphine

Contra-indications

Do not administer by the intrathecal or peridural route.

Do not use pre-operatively for Caesarian section.

Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Special warnings for each target species

None

Special precautions for use

Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression.

In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk associated with the use of the product. The benefit: risk assessment for using the product should be made by the attending vet. Safety has not been fully evaluated in clinically compromised cats.

Buprenorphine should be used with caution in animals with impaired liver function, especially biliary tract disease, as the substance is metabolised by the liver and its intensity and duration of action may be affected in such animals.

The safety of buprenorphine has not been demonstrated in animals less than 7 weeks of age, therefore, use in such animals should be based on the risk: benefit assessment of the veterinarian.

Repeat administration earlier than the recommended repeat interval suggested is not recommended.

Long-term safety of buprenorphine has not been investigated beyond 5 consecutive days of administration in cats or 4 separate administrations on three consecutive days in horses.

The effect of an opioid on head injury is dependent on the type and severity of the injury and the respiratory support supplied. The product should be used in accordance with the benefit:risk assessment of the attending veterinarian.

Safety has not been evaluated in clinically-compromised horses. In horses, use of opioids has been associated with excitation, but effects with buprenorphine are minimal when administered in conjunction with sedatives and tranquilisers such as detomidine, romifidine, xylazine and acepromazine. The safety of buprenorphine has not been demonstrated in horses younger than 10 months old and weighing less than 150kg; therefore, use in such animals should be based on the risk: benefit assessment of the veterinarian.

Ataxia is a known effect of detomidine and similar agents; consequently it may be seen after administration of buprenorphine with such substances. Occasionally, ataxia may be marked. To ensure ataxic horses sedated with detomidine/buprenorphine do not lose their balance, they should not be moved or otherwise handled in any way that would compromise their stability.

Adverse reactions

Salivation, bradycardia, hypothermia, agitation, dehydration and miosis can occur in the dog, and rarely hypertension and tachycardia.

Mydriasis and signs of euphoria (excessive purring, pacing, rubbing) commonly occur in cats and will usually resolve within 24 hours.

Buprenorphine may cause respiratory depression. (refer to section 4.5i)

When used to provide analgesia in horses, sedation is rarely seen, but may occur at dose levels higher than those recommended. When used in conjunction with sedatives or tranquillisers, excitation is normally minimal, but ataxia may occasionally be marked. Colic is rarely reported.

Use during pregnancy or lactation

Pregnancy:

Laboratory studies in rats have not produced any evidence of a teratogenic effect. However, these studies have shown post-implantation losses and early foetal deaths. These may have resulted from a reduction in parental body condition during gestation and in post-natal care owing to sedation of the mothers.

As reproductive toxicity studies have not been conducted in the target species, use only according to the benefit/risk assessment by the responsible veterinarian.

The product should not be used pre-operatively in cases of Caesarean section, due to the risk of respiratory depression in the offspring periparturiently, and should only be used post-operatively with special care (see below).

Lactation:

Studies in lactating rats have shown that, after intramuscular administration of buprenorphine, concentrations of unchanged buprenorphine in the milk equalled or exceeded that in the plasma. As it is likely that buprenorphine will be excreted in the milk of other species, use is not recommended during lactation. Use only according benefit: risk assessment by the responsible veterinarian.

Interactions

Buprenorphine may cause some drowsiness, which may be potentiated by other centrally acting agents, including tranquillisers, sedatives and hypnotics.

There is evidence in humans to indicate that therapeutic doses of buprenorphine do not reduce the analgesic efficacy of standard doses of an opioid agonist, and that when buprenorphine is employed within the normal therapeutic range, standard doses of opioid agonist may be administered before the effects of the former have ended without compromising analgesia. However, it is recommended that buprenorphine is not used in conjunction with morphine or other opioid-type analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or butorphanol.

Buprenorphine has been used with acepromazine, alphaxalone/alphadalone, atropine, detomidine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol, romifidine, sevoflurane, thiopentone and xylazine. When used in combination with sedatives, depressive effects on heart rate and respiration may be augmented.

Amounts to be administered and administration route

Dog and Cat – intramuscular or intravenous injection

Horse - intravenous injection

An appropriately graduated syringe must be used to allow accurate dosing.

Post-Operative Analgesia:

Dog: 10-20 micrograms per kg (0.3-0.6ml per 10kg). For further pain relief, repeat if necessary after 3-4 hours with 10 microgram per kg or 5-6 hours with 20 microgram per kg.

Cat: 10 – 20 microgram per kg (0.3 – 0.6ml per 10kg), repeated if necessary, once, after 1 - 2 hours.

Horse: 10 microgram per kg (3.3 mL per 100 kg), 5 minutes after administration of an iv sedative. The dose may be repeated if necessary, once, after not less than 1 - 2 hours.

Potentiation of Sedation:

Dog: 10-20 micrograms per kg (0.3-0.6ml per 10kg).

Horse: 5 micrograms per kg (1.7mL per 100kg) 5 minutes after administration of an iv sedative. The dose may be repeated if necessary after 10 minutes

In dogs, sedative effects are present by 15 minutes after administration. Analgesic activity may not develop fully until 30 minutes. To ensure that analgesia is present during surgery and immediately on recovery, the product should be administered preoperatively as part of premedication.

When administered for potentiation of sedation or as part of premedication, the dose of other centrally-acting agents, such as acepromazine or medetomidine, should be reduced. The reduction will depend on the degree of sedation required, the individual animal, the type of other agents included in premedication and how anaesthesia is to be induced and maintained. It may also be possible to reduce the amount of inhalational anaesthetic used.

Animals administered opioids possessing sedative and analgesic properties may show variable responses. Therefore, the response of individual animals should be monitored and subsequent doses should be adjusted accordingly. In some cases, repeat doses may fail to provide additional analgesia. In these cases, consideration should be given to using a suitable injectable NSAID.

Overdose

In cases of overdosage, supportive measures should be instituted, and, if appropriate, naloxone or respiratory stimulants may be used.

When administered at overdose to dogs, buprenorphine may cause lethargy. At very high doses, bradycardia and miosis may be observed.

Studies in horses where buprenorphine has been administered with sedatives have shown very few effects at up to five times the recommended dosage, but when administered on its own it may cause excitement in pain-free-animals.

Naloxone may be of benefit in reversing reduced respiratory rate and respiratory stimulants such as Doxapram are also effective in man. Because of the prolonged duration of effect of buprenorphine in comparison to such drugs, they may need to be administered repeatedly or by continuous infusion. Volunteer studies in man have indicated that opiate antagonists may not fully reverse the effects of buprenorphine.

In toxicological studies of buprenorphine hydrochloride in dogs, biliary hyperplasia was observed after oral administration for one year at dose levels of 3.5mg/kg/day and above. Biliary hyperplasia was not observed following daily intramuscular injection of dose levels up to 2.5mg/kg/day for 3 months. This is well in excess of any clinical dose regimen in the dog. See also adverse reaction and special precaution sections.

Withdrawal periods

Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Pharmacological particulars

Pharmacodynamic properties

In summary, buprenorphine is a potent, long-acting analgesic acting at opiate receptors in the central nervous system. Buprenorphine can potentiate the effects of other centrally-acting agents, but unlike most opiates, buprenorphine has, at clinical doses, only a limited sedative effect of its own.

Buprenorphine exerts its analgesic effect via high affinity binding to various subclasses of opiate receptors, particularly µ, in the central nervous system. At clinical dose levels for analgesia, buprenorphine binds to opiate receptors with high affinity and high receptor avidity, such that its dissociation from the receptor site is slow, as demonstrated in in vitro studies. This unique property of buprenorphine could account for its longer duration of activity when compared to morphine. In circumstances where excessive opiate agonist is already bound to opiate receptors, buprenorphine can exert a narcotic antagonistic activity as a consequence of its high-affinity opiate receptor binding, such that an antagonistic effect on morphine equivalent to naloxone has been demonstrated.

Buprenorphine has little effect on gastro-intestinal motility.

Pharmacokinetic properties

Buprenorphine is rapidly absorbed after intramuscular injection in various animal species and man. The substance is highly lipophilic and the volume of distribution in body compartments is large. Pharmacological effects (e.g. mydriasis) may occur within minutes of administration and signs of sedation normally appear by 15 minutes. Analgesic effects in dogs and cats appear around 30 minutes with peak effects usually being observed at about 1 – 1.5 hours. In pain-free horses, antinociceptive effects appear during the first 15 - 30 minutes; peak antinociceptive effects occur between ¾ and 6 hours after administration

Following intravenous administration to dogs at a 20μg/kg dose, the mean terminal half-life was 9 hours and the mean clearance was 24 ml/kg/min, however, there is considerable inter-dog variability in pharmacokinetic parameters.

Following intramuscular administration to cats, the mean terminal half-life was 6.3 hours and the clearance was 23 mL/kg/min; however, there was considerable inter-cat variability in pharmacokinetic parameters.

Following intravenous administration in horses, buprenorphine has a mean residence time of approximately 150 minutes, a volume of distribution of approximately 2.5L/kg and a clearance rate of 10L/minute.

Combined pharmacokinetic and pharmacodynamic studies have demonstrated a marked hysteresis between plasma concentration and analgesic effect. Plasma concentrations of buprenorphine should not be used to formulate individual animal dosage regimens, which should be determined by monitoring the patient’s response.

The major route of excretion in all species except the rabbit (where urinary excretion predominates) is the faeces. Buprenorphine undergoes N-dealkylation and glucuronide conjugation by the intestinal wall and the liver and its metabolites are excreted via the bile into the gastro-intestinal tract.

In tissue distribution studies carried out in rats and rhesus monkeys the highest concentrations of drug-related material were observed in liver, lung and brain.

Peak levels occurred rapidly and declined to low levels by 24 hours after dosing.

Protein binding studies in rats have shown that buprenorphine is highly bound to plasma proteins, principally to alpha and beta globulins.

Pharmaceutical particulars

-

Excipients

Chlorocresol, Glucose anhydrous, Hydrochloric acid (for pH adjustment), Water for injection.

Major incompatibilities

None known

Shelf life

Shelf-life: 2 years

Shelf-life after first opening the immediate packaging: 28 days

Special precautions for storage

Do not store above 25ºC.

Keep the vial in the outer carton in order to protect from light

Shake well before use.

Immediate packaging

Presented in a 10ml amber, Type I glass vial with chlorobutyl rubber stopper, and a 20mm aluminium collar with a flip-off cap.

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements

Marketing Authorisation Holder (if different from distributor)

-

Marketing authorisation number

Vm 14094/4005.

Date of the first authorisation or date of renewal

13 February 2009

Date of revision of the text

July 2012

Any other information

Special precautions for the person administering the veterinary medicinal product to animals: Wash hands/affected area thoroughly after any accidental spillage. As buprenorphine has opioid-like activity, care should be taken to avoid self-injection. In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Following eye contamination or skin contact, wash thoroughly with cold running water. Seek medical advice if irritation persists.

Legal category

POM-V, CD (Sch3)

Vetergesic 0.3 mg/ml Solution for Injection for Dogs and Cats

Qualitative and quantitative composition

Buprenorphine0.3mg/ml (as buprenorphine hydrochloride 0.324 mg/ml)

Pharmaceutical form

Solution for injection. clear, colourless solution for injection

Clinical particulars

Target species

Dogs and cats.

Indications for use

Post-operative analgesia and sedation in the dog. Post-operative analgesia in the cat.

Contra-indications

None known

Special warnings for each target species

Animals administered opioids possessing sedative and analgesic properties may show variable responses. Therefore, the responses of individual animals should be monitored and subsequent doses should be adjusted accordingly. In some cases repeat doses may fail to provide additional analgesia. In these cases, consideration should be given to use of an analgesic from an alternative class.

Special precautions for use

Buprenorphine may occasionally cause significant respiratory depression and, as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression. Volunteer studies in man have indicated that opiate antagonists may not fully reverse the effects of buprenorphine. Naloxone may be of benefit in reversing reduced respiratory rate and respiratory stimulants such as Doxapram are also effective in man. Because of the prolonged duration of effect of buprenorphine in comparison to such drugs, they may need to be administered repeatedly or by continuous infusion.

Buprenorphine may cause some drowsiness, which may be potentiated by other centrally-acting agents, including tranquillisers, sedatives and hypnotics. The product should not be used in conjunction with morphine or other opioid-type analgesics (e.g. etorphine, fentanyl, pethidine, methadone, papaveretum and butorphanol).

As buprenorphine is metabolised by the liver, its intensity and duration of action may be affected in animals with impaired liver function.

Safety has not been fully evaluated in clinically compromised cats e.g. those suffering from renal or hepatic dysfunction, cardiovascular disease or shock. Use in such cases should be based on the risk-benefit assessment of the veterinarian.

Repeated administration earlier than the recommended repeat interval suggested is not recommended.

Adverse reactions

Salivation, bradycardia, hypothermia, agitation, dehydration and meiosis can occur in the dog, and rarely hypertension and tachycardia.

Mydriasis and signs of euphoria (excessive purring, pacing, rubbing) commonly occur in cats and will usually resolve within 24 hours.

Use during pregnancy or lactation

No foetal malformations were noted in reproduction studies in rats when buprenorphine was administered by subcutaneous, intramuscular, or intravenous routes. Although post-implantation losses and early foetal deaths were observed, these may have resulted from a lower level of parental care owing to sedation of the mothers.

The product should not be used pre-operatively in cases of Caesarean section, due to the risk of respiratory depression in the offspring periparturiently, and should only be used post-operatively with care. Although the reproduction studies in animals do not indicate a teratogenic risk, buprenorphine should be used with caution in pregnant animals.

Studies in lactating rats have shown that, after intramuscular administration of buprenorphine, concentrations of unchanged buprenorphine in the milk equalled or exceeded that in the plasma. As it is likely that buprenorphine will be excreted in the milk of other species, care should be taken when administering buprenorphine to lactating animals.

Interactions

Buprenorphine may cause some drowsiness, which may be potentiated by other centrally acting agents, including tranquillisers, sedatives and hypnotics.

Although there is evidence in humans to indicate that therapeutic doses of buprenorphine do not reduce the analgesic efficacy of standard doses of an opioid agonist and that when buprenorphine is employed within the normal therapeutic range, standard doses of opioid agonist may be administered before the effects of the former have ended without compromising analgesia, it is recommended that buprenorphine is not used in conjunction with morphine or other opioid-type analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or butorphanol.

Vetergesic has been used successfully with a wide range of premedicant and anaesthetic agents including acepromazine, alphaxalone/alphadalone, atropine, halothane, isoflurane, ketamine, medetomidine, propofol, sevoflurane, thiopentone and xylazine without any observed adverse effects.

Amounts to be administered and administration route

Vetergesic should be injected intramuscularly. An appropriately graduated syringe must be used to allow accurate dosing.

Post-Operative Analgesia

Dog: 10 – 20 microgram per kg (0.3 – 0.6mL per 10 kg) repeated if necessary after 3 – 4 hours with 10 microgram or 5 – 6 hours with 20 microgram doses.

Cat: 10 – 20 microgram per kg (0.3 – 0.6mL per 10 kg), repeated if necessary, once, after 2 hours.

Sedation:

Dog: 10 – 20 microgram per kg (0.3 – 0.6mL per 10 kg)

To ensure that analgesia is present immediately on recovery, the product can be administered preoperatively. If additional analgesia is subsequently required, this may be achieved by administration of a further dose of Vetergesic or concomitant use of a suitable injectable NSAID.

When administered pre-operatively in conjunction with other premedicants, it may be possible to reduce the amount of premedicant, such as acepromazine or medetomidine, and also the amount of inhalational anaesthetic used.

Overdose

In cases of overdosage, supportive measures should be instituted, and, if appropriate, naloxone or respiratory stimulants may be used. However, dose levels many times higher than those indicated above have been used without serious side effects.

Withdrawal periods

Not Applicable

Pharmacological particulars

Pharmacodynamic properties

In summary buprenorphine is a potent, long-acting analgesic acting at opiate receptors in the central nervous system.

Buprenorphine exerts its analgesic effect via high affinity binding to various subclasses of opiate receptors, particularly µ, in the central nervous system. At clinical dose levels for analgesia, buprenorphine demonstrates high efficacy and binds to opiate receptors with high affinity and high receptor avidity, such that its dissociation from the receptor site is slow, as demonstrated in in vitro studies. This unique property of buprenorphine could account for its longer duration of activity when compared to morphine. In circumstances where excessive opiate agonist is already bound to opiate receptors, buprenorphine can exert a narcotic antagonistic activity as a consequence of its high-affinity opiate receptor binding, such that an antagonistic effect on morphine equivalent to naloxone has been demonstrated.

Pharmacokinetic properties

Buprenorphine is rapidly absorbed after intramuscular injection in various animal species and man. The substance is highly lipophilic and the volume of distribution in body compartments is large. Pharmacological effects occur within 30 minutes after injection and peak effects are usually observed at about 1 – 1.5 hours. Following intramuscular administration to cats, the mean terminal half-life was 6.3 hours and the clearance was 23 mL/kg/min, however, there was considerable inter-cat variability in pharmacokinetic parameters.

Combined pharmacokinetic and pharmacodynamic studies in cats have demonstrated a marked hysteresis between plasma concentrations and analgesic effect. Plasma concentrations of buprenorphine should not be used to formulate individual animal dosage regimens, which should be determined by monitoring of the patient’s response.

The major route of excretion in all species except the rabbit (where urinary excretion predominates) is the faeces. Buprenorphine undergoes N-dealkylation and glucuronide conjugation by the intestinal wall and the liver and its metabolites are excreted via the bile into the gastro-intestinal tract.

In tissue distribution studies carried out in rats and rhesus monkeys the highest concentrations of drug-related material were observed in liver, lung and brain. Peak levels occurred rapidly and declined to low levels by 24 hours after dosing.

Protein binding studies in rats have shown that buprenorphine is highly bound to plasma proteins, principally to alpha and beta globulins.

Pharmaceutical particulars

-

Excipients

Glucose anhydrous, Hydrochloric acid, Dilute (for pH adjustment), Water for injection.

Major incompatibilities

None known

Shelf life

3years.

Special precautions for storage

Do not store above 25ºC. Protect from light.

This product does not contain an antimicrobial preservative. Any solution remaining in an ampoule following withdrawal of the required dose should be discarded.

Immediate packaging

Presented in 1ml clear, Type I glass, snap ampoules, in boxes of five.

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

-

Marketing authorisation number

Vm 14094/4003.

Date of the first authorisation or date of renewal

24th April 1995

Date of revision of the text

July 2012

Any other information

Special precautions to be taken by the person administering the medicinal product to the animals: Wash hands/affected area thoroughly after any accidental spillage. Care should be taken to avoid accidental self-injection. Following accidental self-injection or ingestion, seek medical advice taking the product literature with you. Following eye contamination or skin contact, wash thoroughly with cold running water.

Legal category

POM-V, CD (Sch3)

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Reviews of Vetergesic Injection for Dogs & Cats

Read our customers' reviews of Vetergesic Injection for Dogs & Cats

Questions & Answers for Vetergesic Injection for Dogs & Cats

Below are some recent questions we've received regarding Vetergesic Injection for Dogs & Cats, including answers from our team.

Ask Your Own Question

Should this drug be given to my cat oraly at 0.3

21st Apr 2014
Martin

Is it safe to give this to my 10 year old cat twice a day oraly at 0.3ml as she has gastro limphoma and not on any other drugs at this time
It seems to only advocate by syringe

John Cousins
  • Veterinary Surgeon

Your vet has to prescribe this medication and to advise how it should be used. Although this product is intended to be given by injection, it can be given by mouth and this is sometimes recommended for cats in a home situation.